Catalog No.
DHC21901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
MSK8, VNRA, Vitronectin receptor, Integrin alpha-V, Vitronectin receptor subunit alpha, CD51, ITGAV, VTNR
Concentration
0.61 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06756
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
DI-17E6,EMD 525797, CAS: 1105038-73-0
Clone ID
Abituzumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles., PMID:20031203
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy., PMID:23791392
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?, PMID:23838638
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses., PMID:24242902
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial., PMID:25319061
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer., PMID:26839144
Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression., PMID:28314844
Integrins as Therapeutic Targets: Successes and Cancers., PMID:28832494
Integrin Inhibitors in Prostate Cancer., PMID:29415418
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease., PMID:29893938
Integrins as A New Target for Cancer Treatment., PMID:30451118
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease., PMID:33004536
Integration of NMR Spectroscopy in an Analytical Workflow to Evaluate the Effects of Oxidative Stress on Abituzumab: Beyond the Fingerprint of mAbs., PMID:37278511
Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets., PMID:40304052
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy, PMID: 23791392
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses, PMID: 24242902
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles, PMID: 20031203
A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?, PMID: 23838638
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease, PMID: 29893938
Integrins as Therapeutic Targets: Successes and Cancers, PMID: 28832494
Integrin Inhibitors in Prostate Cancer, PMID: 29415418
Integrins as A New Target for Cancer Treatment, PMID: 30451118
Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer, PMID: 26839144
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial, PMID: 25319061
Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression, PMID: 28314844
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease, PMID: 33004536
For research use only. Not for human or drug use.
